IL5 and asthma: This approach could, therefore, be complimentary or advantageous to currently approved biological therapies, such as omalizumab (anti‐IgE mAb), reslizumab (anti‐IL‐5 mAb) and mepolizumab (IL‐5 antagonist), which generally favour one arm of the allergic response and thus are only effective in specific asthma endotypes.43 Furthermore, blocking ICOS signalling has been proven to be safe and effective in phase I clinical trials for systemic lupus erthymatoesus.44